|drug3379||The demographic, clinical, laboratory, and instrumental data Wiki||1.00|
|drug3188||Standard charity resources Wiki||1.00|
There is one clinical trial.
This study is a single-centre, interventional randomised controlled trial. Participants will be individually randomised to receive either COMPASS online CBT + "usual care" (standard LTC charity support), or usual care only. Randomisation will be stratified by recruiting charity site to ensure a balance of participants with different LTCs across the intervention and control arm. Randomisation will occur using a 1:1 allocation ratio managed by RECAP software. Participants randomised to COMPASS will receive access to the online program. It consists of 11 online modules which target challenges associated with living with LTC(s) and includes, amongst other things, psycho-education, patient examples, interactive tasks and goal setting. Participants are linked to a therapist; 'guide', who will provide 6 x 30 minute support sessions delivered fortnightly in the format preferred by the client (phone and/or in-site message). Participants allocated to the usual care control arm will receive the usual care that is available to them via their charity. All charities include a helpline which can be accessed via telephone or email. The helplines at all charities offer one-off emotional and/or informational support provided by people trained in active listening and/or counselling skills. Additional support avenues that can be accessed may include online support groups, local community support groups and informational resources.
Description: A composite measure of Generalised Anxiety Disorder questionnaire (GAD-7) and Patient Health Questionnaire (PHQ-9). Min score = 0, Max score = 48, with higher scores indicating higher levels of distress.Measure: Change in Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS) Time: At baseline, 6 weeks (mid-therapy) and 12 weeks (end of therapy)
Description: Social functioning. Min score = 0, Max score = 40 , with higher scores indicating greater functional impairment.Measure: Change in Work and social adjustment scale (WSAS) Time: At baseline, 6 weeks (mid-therapy) and 12 weeks (end of therapy)
Description: Quality of life. Min score = 5, Max score = 15 , with higher scores more problems in the scale dimensions.Measure: Change in EQ-5D-3L Time: At baseline, 6 weeks (mid-therapy) and 12 weeks (end of therapy)
Description: IPQ-R tailored to COVID-19 to establish emotional responses regarding the COVID-19 pandemic. Min score = 0, Max score = 24 , with higher scores indicating higher emotional responses.Measure: Change in Illness perception questionnaire - revised (IPQ-R), emotional subscale Time: At baseline, 6 weeks (mid-therapy) and 12 weeks (end of therapy)
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports